Immunization Record
Immunization Record
Ishamma T M
| Vaccine | Date | Lot # | Site | Provider | Source |
|---|---|---|---|---|---|
| Zoster vaccine (presumed Zostavax) | ~2016 (approximate) | Unknown | Unknown | Unknown | Patient report (2026-04-17) |
[!info] Zostavax vs. Shingrix
The vaccine given ~2016 was most likely Zostavax (live attenuated). Efficacy wanes significantly after 5–8 years. Shingrix (recombinant, 2-dose series) is the current standard and should be discussed with Bijay Prabhakaran Nair once immunosuppression resolves. Shingrix is recommended even for patients who previously received Zostavax.
The following vaccinations are NOT documented and should be discussed with the treating oncologist:
- Influenza (annual)
- COVID-19 (per ACIP guidance)
- Pneumococcal (PCV20)
- Shingrix (deferred during active chemotherapy)Live vaccines are CONTRAINDICATED during active Aza-Ven chemotherapy. Timing of inactivated vaccines relative to chemo cycles matters — coordinate with Bijay Prabhakaran Nair.